Galera Therapeutics (GRTX) AI Stock Analysis

• Market Cap: $1.89M
• Dividend Yield: N/A
• Average Volume (3M): 102.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: N/A
• EPS Growth: 75.56%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 75,462,390
• 10 Day Avg. Volume: 90,886
• 30 Day Avg. Volume: 102,935
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Galera Therapeutics exhibits significant financial instability with consistent losses and negative equity, heavily impacting its overall score. The technical analysis indicates bearish market momentum, and the valuation is unattractive with a negative P/E ratio. The absence of positive earnings call data or corporate events further contributes to the poor stock performance outlook.

Galera Therapeutics Business Overview & Revenue Model

Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

How the Company Makes Money

Galera Therapeutics primarily makes money through the development and commercialization of its drug candidates. As a clinical-stage company, its revenue model is largely centered on successful clinical trials leading to regulatory approvals and subsequent commercialization of its products. Revenue streams may include milestone payments, licensing agreements, and potentially sales revenue once its therapeutics receive regulatory approval. Additionally, Galera may engage in strategic partnerships with larger pharmaceutical companies to enhance the development and distribution of its therapies, which could also contribute to its financial earnings.

Galera Therapeutics Financial Statement Overview

Summary

Galera Therapeutics faces significant financial challenges with persistent losses, negative equity, and cash flow difficulties. The lack of revenue and profitability, combined with an unstable balance sheet, pose substantial risks to financial sustainability. The company needs to address these issues to improve its financial health and long-term viability.

Income Statement

Galera Therapeutics has consistently reported negative net income, with no revenue growth over the years. The company has not generated revenue from its operations, leading to negative gross and net profit margins. The EBIT and EBITDA margins are also negative, indicating significant operating losses. The lack of revenue growth and continuous losses reflect challenges in achieving profitability.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant financial risk. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is negative, highlighting financial instability. This reflects underlying financial weaknesses and potential solvency issues.

Cash Flow

Despite negative operating cash flow and free cash flow, there is a slight reduction in cash outflows over time. The company has been able to manage its financing activities to support cash needs, but the free cash flow growth remains negative. The ratios of operating and free cash flow to net income are not favorable, indicating cash flow challenges.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
88.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-136.00K	-259.00K	-114.00K	-778.00K	-368.00K	-267.00K
	EBIT
-19.87M	-46.95M	-51.23M	-73.37M	-70.55M	-50.69M
	EBITDA
-19.37M	-46.69M	-50.61M	-72.56M	-69.01M	-50.69M
	Net Income Common Stockholders
-19.61M	-59.08M	-62.22M	-87.73M	-74.22M	-51.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
81.52M	18.26M	31.60M	71.22M	72.78M	112.29M
	Total Assets
88.06M	26.14M	44.04M	83.31M	84.10M	123.38M
	Total Debt
0.00	1.25M	44.00K	302.00K	534.00K	831.00K
	Net Debt
-14.81M	-17.01M	-4.22M	-19.56M	-15.34M	-17.52M
	Total Liabilities
192.88M	157.33M	153.22M	141.31M	77.98M	53.77M
	Stockholders Equity
-104.82M	-131.19M	-109.18M	-58.00M	6.12M	69.61M
Cash Flow		Free Cash Flow
-9.92M	-44.91M	-43.45M	-68.24M	-59.99M	-47.29M
	Operating Cash Flow
-9.91M	-44.85M	-43.43M	-67.96M	-59.54M	-46.66M
	Investing Cash Flow
3.98M	27.29M	23.99M	5.24M	36.55M	-27.82M
	Financing Cash Flow
-232.00K	31.50M	3.89M	66.71M	20.51M	78.03M

Galera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.60 is Neutral, neither overbought nor oversold. The STOCH value of -75.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRTX.

Galera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$1.83M	7.93	99.42%	―	―	―
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
INM	44 Neutral	$3.60M	―	-83.50%	―	-11.94%	56.72%
EYEN	38 Underperform	$3.09M	―	-388.03%	―	1414.02%	-14.78%
SHPH	32 Underperform	$1.57M	―	-383.84%	―	―	-7.18%
REVB	28 Underperform	$2.90M	―	-264.85%	―	―	-115.81%
GRTX	22 Underperform	$1.89M	―	13.71%	―	―	75.56%

Galera Therapeutics Corporate Events

Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition

Galera Therapeutics has completed the acquisition of Nova Pharmaceuticals, which focuses on developing a pan-NOS inhibitor to treat resistant forms of breast cancer. The merger shifts Galera’s strategy towards anti-cancer therapeutics, with plans for multiple clinical trials, including a Phase 1/2 trial for metaplastic breast cancer. This acquisition is expected to bolster Galera’s financial and operational capabilities, with support from investors and strategic partnerships to fund developments through 2026.